Human monoclonal antibody against TGF-β type II receptor and medicinal use thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 25, 2009
Grant Date -
N/A
app pub date -
Nov 17, 2000
filing date -
Nov 18, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Various human monoclonal antibodies that bind to human TGF-β type II receptor to inhibit the signal transduction of human TGF-β signal into cells are produced by immunizing human antibody-producing transgenic mice generated by genetic engineering techniques with the soluble human TGF-β type II receptor. Further, these human monoclonal antibodies were demonstrated to be effective for preventing and treating various diseases induced by human TGF-β in various organs (for example, tissue fibrosis).
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully